RxDoctor Payments Data

Blanche Fung-Liu, MD

Internal Medicine · Great Neck, NYNPI 1386649846

Payments from drug & device makers

$682,847in general payments, 2019–2025

Across 380 payments — averaging $1796.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$223K
  • Pfizer$146K
  • E.r. Squibb & Sons, L.L.C.$134K
  • Eli Lilly$101K
  • Genentech, Inc.$51K
  • UCB Biosciences Inc.$13K
  • plus $15K from 16 others
$94in research payments, 2019–2025

Across 1 payment — averaging $94.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$94

What the payments were for

  • Food & beverage$2,846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$682,847 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$183,143
Medicare patients
425
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$522,351
Humira(Cf) PenAdalimumab22$149,853
Mesalamine40$24,130
LinzessLinaclotide16$19,716
CreonLipase/Protease/Amylase21$17,097
MotofenDifenoxin Hcl/Atropine Sulfate12$8,542
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates85$5,012
SutabSod Sulf/Pot Chloride/Mag Sulf29$4,670
CholestyramineCholestyramine (With Sugar)15$2,319
Omeprazole128$1,860
Sucralfate14$1,653
Pantoprazole Sodium58$1,393
Famotidine45$996
Rabeprazole Sodium16$606
Esomeprazole Magnesium12$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$161$522,35119 claims
AbbVieLinzess, Creon$3,140$36,81337 claims
Braintree Laboratories, Inc.Motofen, Sutab$29$13,21241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →